Treatment of ampullary neuroendocrine tumor by Capecitabine (Xeloda®) and Temozolomide (Temodal®)

Sima Noorali, Shirin Haghighi
Department of Hematology & Oncology, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran

ABSTRACT
Neuroendocrine tumors of the gastrointestinal tract and pancreas include a range of rare and diverse neoplasms with unique tumor biology, natural history, and clinical management. Neuroendocrine tumors of the ampulla of Vater are extremely uncommon cancers that account for only about 0.3%-1% of all gastrointestinal neuroendocrine tumors. Approximately 139 cases have been reported to date. In this paper, we describe two patients with low to intermediate grades of ampullary neuroendocrine tumors that underwent multiple courses of chemotherapy with Capecitabine (Xeloda®) and Temozolomide (Temodal®). Our two patients had a dramatic response to this regimen. According to our study, it seems that ampullary neuroendocrine tumors have behavior like pancreatic neuroendocrine tumors which requires further studies in more patients.

Keywords: Neuroendocrine tumors, Vater's ampulla, Capecitabine, Temozolomide.

Case Reports
Case 1
the first case was forty years old female. The patient complained of itching and mild epigastric pain that started 2 weeks before referring to our hospital. Past medical history was unremarkable. She had a history of gastric adenocarcinoma in her father who died two years after diagnosis (the time of third debulking surgery). Physical examination revealed a generalized Jaundice. Laboratory findings showed the total and direct levels of bilirubin 17.3 and 11.3 mg/dl, respectively. In the endosonography, there was a 25*30 millimeters (mm) hypoechoic mass lesion at the ampulla and a 10-mm regional lymphadenopathy. Endoscopy showed ulcerative vegetative 22*17 mm lesion around the ampulla where biopsies were taken. Pathological examination suggested a well-differentiated NET (Grade 2) confirmed with Immunohistochemical (IHC) study which was positive for Synaptophysin, Chromogranin A (127). In this examination, Ki-67 was 4%. Computed tomography (CT) scan showed a periamputillary mass (30*50 mm) resulted in extrahepatic and intrahepatic biliary...
dilatation. The maximum diameter of the common bile duct (CBD) was measured at 14 mm. The mass only partially touches the portal vein without a definite sign of invasion. During three months, she received three courses of chemotherapy with Capecitabine (Xeloda®- Roche company - 750 mg/m2- Two weeks of every three weeks) and Temozolomide (Temodal®- 200 mg/m2- The tenth day until the fourteenth) with a partial response based on RECIST criteria on CT scan. After three months, Whipple surgery was performed with complete R0 resection. In four years of follow-up, she is still in clinical remission.

Discussion

NETs represent 0.5% of all cancers; however, their incidence has risen in recent years, probably due to the increased frequency of healthcare examinations and improvements in diagnostic techniques (4). NETs can be part of familial cancer syndromes such as Neurofibromatosis type 1 (NF1), Multiple Endocrine Neoplasia type 1 (MEN1), Von Hippel-Lindau (VHL) syndrome or Tuberous Sclerosis (TS) but most of them are sporadic (3). They have been detected in the esophagus, stomach, duodenum, small bowel, pancreas, colon, rectum, bronchus, ovary, testis, larynx, and biliary tract, and may differ in their response to treatment depending on their site of origin (1,2). Also, NETs of the gastrointestinal tract and pancreas include a range of rare and diverse neoplasms with unique tumor biology, natural history, and clinical management issues (3). The most common NETs are pancreatic islet cell tumors and carcinoid tumors that represent only 2% of all gastrointestinal malignant neoplasms (4). However, NETs of the ampulla of Vater are an extremely uncommon subset of pancreatic cancers that account for only about 0.3%-1% of all gastrointestinal NETs (5,6). Approximately 139 cases have been reported to date, and only about 20% of these reported patients are of African or Asian Pacific origin (6).

Clinical presentations consist of jaundice, nonspecific upper abdominal discomfort, acute pancreatitis, weight loss, and upper gastrointestinal bleeding; but the leading symptom in approximately two-thirds of the patients is jaundice (7,8).

In addition to clinical findings, abdominal tomography, ERCP, endoscopic biopsy, and endosonography are also valuable in the diagnosis and detection of invasion depth; also, CT scans and octreotide scans are helpful in metastatic workup (6,7). Staining of ampullary neuroendocrine tumors (ANETs) with Chromogranin A and Synaptophysin is positive in 92-100% cases (6). ANET frequently originates from the deep mucosa or submucosa, so it cannot be easily detected in biopsy specimens and there is a high rate of
false-negative or inconclusive biopsies making its diagnosis challenging till now (5,9).

ANETs are so rare, so significant questions regarding their natural history remain unanswered (10). Common sites of metastases are usually the lymph nodes and liver (9). Tumor grade and distant metastasis are the most important factors in determining survival and prognosis in ANETs. Other prognostic factors, like nodal involvement, tumor size, and resection margins, appear to be of lesser significance in predicting long-term survival (6,11). The overall five-year survival of patients with resected ANETs is 90% for well-differentiated tumors but is lesser in tumors with lower differentiation. Low-grade NETs show 5- and 10-year survival rates of 80% and 71%, respectively; in contrast, the high-grade NETs have 10-year survival rates of 15% (9).

Optimal treatment for localized PNETs is surgical resection and for tumors that are too advanced to surgically resect, some chemotherapy regimens are effective. Recent studies examined the role of Capecitabine (Xeloda®) and Temozolomide (Temodal®) combination in well-differentiated and unresectable pancreatic neuroendocrine tumors (PNETs) and showed a high response rate (13-18). Sunitinib (Sutent®) is also a multi-targeted tyrosine kinase inhibitor that has become integrated into the treatment of progressive well-differentiated PNETs (14-16). In ampullary tumors, in most studies, the treatment of choice for neuroendocrine tumors of the ampulla of Vater is complete resection (5-7,9,12).

According to one study, a patient with a metastatic neuroendocrine tumor of the ampulla of Vater underwent chemotherapy with Sunitinib (Sutent®) and complete remission was achieved (19); and as mentioned before, Sunitinib (Sutent®) is used to for the treatment of PNETs (14-16). Our two patients had low to intermediate grades of ANETs and they received multiple courses of systemic chemotherapy with Capecitabine (Xeloda®) and Temozolomide (Temodal®) with good response to this regimen.

Based on the above argument, and good responses of patients to Capecitabine and Temozolomide, it seems that ANETs have behavior like PNETs requiring further studies in a larger number of patients.

**Conflict of interests**

The authors declare that they have no conflict of interest.

**References**

1. Kulke MH, Siu LL, Tepper JE, Fisher G, Jaffe D, Haller DG, et al. Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol 2011;29:934-43.

2. Ricci JL. Carcinoid of the ampulla of Vater. Local resection or pancreaticoduodenectomy. Cancer 1993;71:686-90.

3. Neychev V, Steinberg SM, Cottle-Delisle C, Merkel R, Nilubol N, Yao J, et al. Mutation-targeted therapy with sunitinib or everolimus in patients with advanced low-grade or intermediate-grade neuroendocrine tumors of the gastrointestinal tract and pancreas with or without cytoreductive surgery: protocol for a phase II clinical trial. BMJ Open 2015;5:e008248.

4. Mohammed TA, Holen KD, Jaskula-Sztul R, Mulkerin D, Lubner SJ, Schelman WR, et al. A pilot phase II study of valproic acid for treatment of low-grade neuroendocrine carcinoma. Theoncologist 2011;16:835-43.

5. Ho Lee S, Hoon Lee T, Jang SH, Choi ChY, Myung Lee W, Min JH, et al. Ampillary neuroendocrine tumor diagnosed by endoscopic papillectomy in previously confirmed ampillary adenoma. World J Gastroenterol 2016;22:3687-92.

6. Jayant M, Punia R, Kaushik R, Sharma R, Sachdev A, Nadkarni NK, et al. Neuroendocrine tumors of the ampulla of vater: presentation, pathology and prognosis. JOP 2012;13:263-7.

7. Odabasi M, Yildiz KM, Cengiz E, Hasan AH, Gunay E, Ozkan E, et al. Treatment of ampullary neuroendocrine tumor by endoscopic snare papillectomy. Am J Case Rep 2013;14:439-43.

8. Hatzitheoklitos E, Büchler MW, Friess H, Poch B, Ebert M, Mohr W, et al. Carcinoid of the ampulla of Vater. Clinical characteristics and morphologic features. Cancer 1994;73:1580-8.

9. Waisberg J, Joppert-Netto G, Yonamine RY, Waisberg DR. Neuroendocrine Tumor of the Ampulla of Vater: A Rare Neoplasm in an Atypical Site. Rep Three Cases Rev Lit JOP 2016;17:538-42.

10. Carter JT, Grenert JP, Rubenstein L, Stewart L, Way LW. Neuroendocrine tumors of the ampulla of Vater: biological behavior and surgical management. Arch Surg 2009;144:527-31.

11. Ofosu A, Taccone M, Potakamuri L, Jagannath S. Ampullary Neuroendocrine Tumor: A Rare Cause of Recurrent Abdominal Pain. Crcm 2014;3:139-44.

12. Tsukagoshi M, Hosouchi Y, Araki K, Mochida Y, Aihara R, Shirabe K, et al. Neuroendocrine tumor of the ampulla of
Vater with distant cystic lymph node metastasis: a case report. Surg Case Rep 2016;2:73.

13. Abbasi S, Kashashna A, Albaba H. Efficacy of capecitabine and Temozolomide combination in well-differentiated neuroendocrine tumors: Jordan experience. Pancreas 2014;43:1303-5.

14. Mahjoub AR, O'Reilly EM. Emerging therapies for pancreas neuroendocrine cancers. Chin Clin Oncol 2013;2:23.

15. Devata S, Kim EJ. Neoadjuvant chemotherapy with capecitabine and Temozolomide for unresectable pancreatic neuroendocrine tumor. Case Rep Oncol 2012;5:622-6.

16. Strosberg J. Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs). Gastrointest Cancer Res 2013;6:S10-2.

17. Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L. First-line chemotherapy with capecitabine and Temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268-75.

18. Miljković MD, Girotra M, Abraham RR, Erlich RB. Novel medical therapies of recurrent and metastatic gastroenteropancreatic neuroendocrine tumors. Dig Dis Sci 2012;57:9-18.

19. Yang K, Yun SP, Kim S, Shin N, Park DY, Seo HI. Clinicopathological features and surgical outcomes of neuroendocrine tumors of ampulla of Vater. BMC Gastroenterol 2017;17:70.